1. In Vivo

The E In ESG: Sustainability Goals Do Not Exempt Companies From Antitrust Compliance

 
• By Ashley Yeo

Regulatory interventions are the preferred route for ensuring sustainability compliance, says the OECD. Legal firm CMS notes that some ESG objectives may be in contravention of antitrust law. The EU is preparing guidelines on horizontal competition with a renewed focus on sustainability.

EU Green Deal
• Source: Shutterstock

More and more initiatives are being advanced to promote environmental compliance and sustainability. As In Vivo’s “E in ESG” series has described, health care companies and the life sciences industries are not exempt from the societal drive to slow the acceleration of climate change.

The duty of patient care means that providers and the medtech industry have a unique role in how they ensure compliance with green initiatives. While non-reusable products ostensibly do not...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ESG

More from In Vivo

US Health System Redesign Critical, NAM’s Medical Experts Warn Trump Government

 
• By Ashley Yeo

The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.

Podcast: “Powerful Yet Unexplored”: Commit Biologics Tackles The Complement System

 
• By Anabel Costa-Ferreira

Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.

ML-Assisted Genetic Risk Score Predicts GLP-1 Adverse Events

 
• By David Wild

Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.